Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 7/20 | 0.44 |
| ▸ | GSK3B | P49841 | 7/20 | 0.44 |
| ▸ | AURKA | O14965 | 4/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.39 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.36 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13303705 | 0.88 | GSK3A (0.59) | GSK3AGSK3BAURKAALKTBK1 | |
| SCHEMBL13764024 | 0.87 | GSK3A (0.44) | GSK3AGSK3BAURKAEIF2AK4 | |
| SCHEMBL13764008 | 0.86 | GSK3A (0.45) | GSK3AGSK3BAURKAMAPK6FLT3 | |
| SCHEMBL13763989 | 0.86 | GSK3A (0.47) | GSK3AGSK3BAURKAALKTBK1 | |
| SCHEMBL8297236 | 0.85 | GSK3A (0.45) | GSK3AGSK3BAURKAALKTBK1 | |
| SCHEMBL13763994 | 0.83 | GSK3B (0.65) | GSK3AGSK3BAURKAMAPK6JAK2 | |
| SCHEMBL13763998 | 0.83 | GSK3A (0.49) | GSK3AGSK3BAURKATBK1MAPK6 | |
| SCHEMBL13763992 | 0.83 | GSK3A (0.54) | GSK3AGSK3BAURKAMAPK6JAK2 | |
| SCHEMBL13763995 | 0.83 | GSK3A (0.57) | GSK3AGSK3BAURKAALKMAPK6 | |
| SCHEMBL13763996 | 0.83 | GSK3A (0.57) | GSK3AGSK3BAURKAALKTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560458-B2 | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-14 | — | — | US | disclosed |
| US-7560458-B2 | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-14 | — | — | US | disclosed |
| US-20090036471-A1 | Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors | EDGARD EDDY JEAN | 2009-02-05 | — | — | US | disclosed |
| US-20090036471-A1 | Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors | EDGARD EDDY JEAN | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036471-A1 | Triazolopyrimidine Derivatives As Glycogen Synthase Kinase 3 Inhibitors | GSK3B, GSK3A, GYS2 | GSK3A 2/4885GSK3B 1/4885AURKA 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.